Compare iShares Core S&P 500 ETF (IVV) vs Novartis AG (NVS) Price & Performance

iShares Core S&P 500 ETFTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Novartis AG — how do they compare? iShares Core S&P 500 ETF trades at $748.93, while Novartis AG trades at $154.94 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

	IVV	NVS
Sector	Broad Market / Factor	Health
52-Week High	$763.10	$168.62
52-Week Low	$624.65	$113.50
Market Cap	—	$290.25B
Enterprise Value	—	$330.27B
Dividend Yield	—	3.17%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.

Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.

Novartis AG

Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.

Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 1 day agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 2 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 3 days agoBearish View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 13 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.